Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
PURPOSE
To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC).
METHODS
ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population.
RESULTS
Nine phase III randomized controlled trials met the inclusion criteria.
RECOMMENDATIONS
Atezolizumab + bevacizumab (atezo + bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines. Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Child-Pugh class A liver disease, and ECOG PS 0-1. Following first-line treatment with atezo + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may be recommended for appropriate candidates. Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, regorafenib for patients who previously tolerated sorafenib, or ramucirumab (for patients with α-fetoprotein ≥ 400 ng/mL), or atezo + bev where patients did not have access to this option as first-line therapy. Pembrolizumab or nivolumab are also reasonable options for appropriate patients following sorafenib or lenvatinib. Consideration of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed. Further guidance on choosing between therapy options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Top-30
Journals
|
5
10
15
20
25
30
|
|
|
Cancers
29 publications, 6.32%
|
|
|
Journal of Hepatocellular Carcinoma
22 publications, 4.79%
|
|
|
Frontiers in Oncology
20 publications, 4.36%
|
|
|
Liver Cancer
13 publications, 2.83%
|
|
|
Frontiers in Immunology
9 publications, 1.96%
|
|
|
Current Oncology
8 publications, 1.74%
|
|
|
Liver International
8 publications, 1.74%
|
|
|
International Journal of Molecular Sciences
7 publications, 1.53%
|
|
|
Cancer Medicine
6 publications, 1.31%
|
|
|
Hepatology Research
6 publications, 1.31%
|
|
|
Hepatology
5 publications, 1.09%
|
|
|
Cell Death and Disease
5 publications, 1.09%
|
|
|
Biomedicines
4 publications, 0.87%
|
|
|
Medicine (United States)
4 publications, 0.87%
|
|
|
World Journal of Gastrointestinal Oncology
4 publications, 0.87%
|
|
|
World Journal of Gastroenterology
4 publications, 0.87%
|
|
|
Frontiers in Pharmacology
4 publications, 0.87%
|
|
|
Scientific Reports
4 publications, 0.87%
|
|
|
Journal of Hepatology
3 publications, 0.65%
|
|
|
PLoS ONE
3 publications, 0.65%
|
|
|
Cells
3 publications, 0.65%
|
|
|
Journal of Clinical Medicine
3 publications, 0.65%
|
|
|
Frontiers in Medicine
3 publications, 0.65%
|
|
|
Pharmaceutics
3 publications, 0.65%
|
|
|
Nature Reviews Gastroenterology and Hepatology
3 publications, 0.65%
|
|
|
Hepatology International
3 publications, 0.65%
|
|
|
BMC Gastroenterology
3 publications, 0.65%
|
|
|
Cellular and Molecular Gastroenterology and Hepatology
3 publications, 0.65%
|
|
|
BioScience Trends
3 publications, 0.65%
|
|
|
5
10
15
20
25
30
|
Publishers
|
10
20
30
40
50
60
70
80
90
|
|
|
Springer Nature
87 publications, 18.95%
|
|
|
MDPI
68 publications, 14.81%
|
|
|
Elsevier
66 publications, 14.38%
|
|
|
Frontiers Media S.A.
44 publications, 9.59%
|
|
|
Wiley
38 publications, 8.28%
|
|
|
Taylor & Francis
34 publications, 7.41%
|
|
|
S. Karger AG
16 publications, 3.49%
|
|
|
Baishideng Publishing Group
12 publications, 2.61%
|
|
|
AME Publishing Company
11 publications, 2.4%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
10 publications, 2.18%
|
|
|
American Chemical Society (ACS)
5 publications, 1.09%
|
|
|
BMJ
5 publications, 1.09%
|
|
|
American Society of Clinical Oncology (ASCO)
4 publications, 0.87%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 0.87%
|
|
|
Public Library of Science (PLoS)
3 publications, 0.65%
|
|
|
SAGE
3 publications, 0.65%
|
|
|
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
3 publications, 0.65%
|
|
|
Georg Thieme Verlag KG
3 publications, 0.65%
|
|
|
Oxford University Press
3 publications, 0.65%
|
|
|
American Medical Association (AMA)
3 publications, 0.65%
|
|
|
American Association for Cancer Research (AACR)
3 publications, 0.65%
|
|
|
OAE Publishing Inc.
3 publications, 0.65%
|
|
|
Hindawi Limited
2 publications, 0.44%
|
|
|
Hans Publishers
2 publications, 0.44%
|
|
|
Spandidos Publications
2 publications, 0.44%
|
|
|
American Society for Clinical Investigation
1 publication, 0.22%
|
|
|
Mary Ann Liebert
1 publication, 0.22%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.22%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.22%
|
|
|
10
20
30
40
50
60
70
80
90
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.